Do urinary mast cell mediators predict immune response to BCG in patients with primary high‐grade non‐muscle invasive bladder cancer?
Background Mast cells play a critical role in cancer‐associated immunity. We aimed to determine the predictive value of urinary mast cell mediators in patients with non‐muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette‐Guérin (BCG) immunotherapy. Methods In this prospective study...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical practice (Esher) 2021-05, Vol.75 (5), p.e13959-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 5 |
| container_start_page | e13959 |
| container_title | International journal of clinical practice (Esher) |
| container_volume | 75 |
| creator | Simsekoglu, Muhammed Fatih Kaleler, Islim Onal, Bulent Demirdag, Cetin Citgez, Sinharib Uslu, Ezel Erozenci, Ahmet Talat, Zubeyr |
| description | Background
Mast cells play a critical role in cancer‐associated immunity. We aimed to determine the predictive value of urinary mast cell mediators in patients with non‐muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette‐Guérin (BCG) immunotherapy.
Methods
In this prospective study, 19 patients who received immunotherapy because of NMIBC (Group 1) and 19 healthy participants (Group 2) were enrolled. Urine samples were collected to assay N‐methylhistamine, histamine, and tryptase levels immediately before the first BCG instillation, immediately after the third and sixth instillations, and 4 weeks after the sixth instillation in Group 1 and at a single visit in Group 2. The changes in urinary markers because of BCC response, BCG instillation, and the presence of NMIBC were assessed.
Results
The average age was 56.1 ± 10.5 years in Group 1 and 52.6 ± 9.7 years in Group 2. Fourteen patients had high‐grade Ta tumours and five had T1 tumours. While 12 patients had responded to the BCG, seven patients did not respond to the BCG. There was no correlation between mast cell mediators and BCG response. The N‐methylhistamine and histamine levels significantly increased with the onset of immunotherapy, and N‐methylhistamine levels significantly decreased when immunotherapy was terminated (P |
| doi_str_mv | 10.1111/ijcp.13959 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2473407635</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2515975952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3939-cfd366960483446fa7b2e0c80a67ce8a7eaf187d187ea03ba02bc18f9a57e4de3</originalsourceid><addsrcrecordid>eNp9kbFu1TAUhi1ERUth4QGQJRaElGLHcRxPCC7QFlWCAWbrxDnp9VViBztp1Y21W5-xT1Jf7oWBAUuW_-HzJ_v8hLzg7ITn9dZt7HTChZb6ETniqioLXlb8cc6ibgrJBD8kT1PaMFZK2bAn5FAIUWsm9RG5_RjoEp2HeENHSDO1OAx0xM7BHGKiU8zRztSN4-KRRkxT8AnpHOiH1Sl1nk4wO_RzotduXmfejVvX2l2u73_dXUbokPrgcx6XZAfMV64guSuk7QBdh5Fa8Bbju2fkoIch4fP9eUx-fP70fXVWXHw9PV-9vyis0EIXtu9EXeuaVY2oqroH1ZbIbMOgVhYbUAg9b1SXNwITLbCytbzpNUiFVYfimLzeeacYfi6YZjO6tP01eAxLMmWlRMVULWRGX_2DbsISfX6dKSWXWkkty0y92VE2hpQi9mY_BMOZ2RZktgWZ3wVl-OVeubR5yn_RP41kgO-AazfgzX9U5vzL6ttO-gAqdp7z</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2515975952</pqid></control><display><type>article</type><title>Do urinary mast cell mediators predict immune response to BCG in patients with primary high‐grade non‐muscle invasive bladder cancer?</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Simsekoglu, Muhammed Fatih ; Kaleler, Islim ; Onal, Bulent ; Demirdag, Cetin ; Citgez, Sinharib ; Uslu, Ezel ; Erozenci, Ahmet ; Talat, Zubeyr</creator><creatorcontrib>Simsekoglu, Muhammed Fatih ; Kaleler, Islim ; Onal, Bulent ; Demirdag, Cetin ; Citgez, Sinharib ; Uslu, Ezel ; Erozenci, Ahmet ; Talat, Zubeyr</creatorcontrib><description>Background
Mast cells play a critical role in cancer‐associated immunity. We aimed to determine the predictive value of urinary mast cell mediators in patients with non‐muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette‐Guérin (BCG) immunotherapy.
Methods
In this prospective study, 19 patients who received immunotherapy because of NMIBC (Group 1) and 19 healthy participants (Group 2) were enrolled. Urine samples were collected to assay N‐methylhistamine, histamine, and tryptase levels immediately before the first BCG instillation, immediately after the third and sixth instillations, and 4 weeks after the sixth instillation in Group 1 and at a single visit in Group 2. The changes in urinary markers because of BCC response, BCG instillation, and the presence of NMIBC were assessed.
Results
The average age was 56.1 ± 10.5 years in Group 1 and 52.6 ± 9.7 years in Group 2. Fourteen patients had high‐grade Ta tumours and five had T1 tumours. While 12 patients had responded to the BCG, seven patients did not respond to the BCG. There was no correlation between mast cell mediators and BCG response. The N‐methylhistamine and histamine levels significantly increased with the onset of immunotherapy, and N‐methylhistamine levels significantly decreased when immunotherapy was terminated (P < .05). The pre‐BCG estimated marginal mean values of N‐methylhistamine were significantly higher in Group 1 than in Group 2 (P < .05).
Conclusions
Our study is the first to identify the changes in mast cell mediators with the onset of immunotherapy and in presence of bladder cancer. However, these mediators cannot predict patients’ response to immunotherapy.</description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1111/ijcp.13959</identifier><identifier>PMID: 33369059</identifier><language>eng</language><publisher>England: Hindawi Limited</publisher><subject>Administration, Intravesical ; Aged ; BCG Vaccine - therapeutic use ; Bladder cancer ; Cancer ; Histamine ; Humans ; Immune response ; Immunity ; Immunotherapy ; Invasiveness ; Mast Cells ; Middle Aged ; Neoplasm Recurrence, Local ; Prospective Studies ; Tryptase ; Tumors ; Urinary Bladder Neoplasms - drug therapy</subject><ispartof>International journal of clinical practice (Esher), 2021-05, Vol.75 (5), p.e13959-n/a</ispartof><rights>2020 John Wiley & Sons Ltd</rights><rights>2020 John Wiley & Sons Ltd.</rights><rights>Copyright © 2021 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3939-cfd366960483446fa7b2e0c80a67ce8a7eaf187d187ea03ba02bc18f9a57e4de3</citedby><cites>FETCH-LOGICAL-c3939-cfd366960483446fa7b2e0c80a67ce8a7eaf187d187ea03ba02bc18f9a57e4de3</cites><orcidid>0000-0002-8912-9155 ; 0000-0002-2712-7955 ; 0000-0003-0540-2693 ; 0000-0003-0645-4129 ; 0000-0003-3925-0851 ; 0000-0001-7577-7955 ; 0000-0002-3897-2951 ; 0000-0002-6389-5353</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fijcp.13959$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fijcp.13959$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33369059$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Simsekoglu, Muhammed Fatih</creatorcontrib><creatorcontrib>Kaleler, Islim</creatorcontrib><creatorcontrib>Onal, Bulent</creatorcontrib><creatorcontrib>Demirdag, Cetin</creatorcontrib><creatorcontrib>Citgez, Sinharib</creatorcontrib><creatorcontrib>Uslu, Ezel</creatorcontrib><creatorcontrib>Erozenci, Ahmet</creatorcontrib><creatorcontrib>Talat, Zubeyr</creatorcontrib><title>Do urinary mast cell mediators predict immune response to BCG in patients with primary high‐grade non‐muscle invasive bladder cancer?</title><title>International journal of clinical practice (Esher)</title><addtitle>Int J Clin Pract</addtitle><description>Background
Mast cells play a critical role in cancer‐associated immunity. We aimed to determine the predictive value of urinary mast cell mediators in patients with non‐muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette‐Guérin (BCG) immunotherapy.
Methods
In this prospective study, 19 patients who received immunotherapy because of NMIBC (Group 1) and 19 healthy participants (Group 2) were enrolled. Urine samples were collected to assay N‐methylhistamine, histamine, and tryptase levels immediately before the first BCG instillation, immediately after the third and sixth instillations, and 4 weeks after the sixth instillation in Group 1 and at a single visit in Group 2. The changes in urinary markers because of BCC response, BCG instillation, and the presence of NMIBC were assessed.
Results
The average age was 56.1 ± 10.5 years in Group 1 and 52.6 ± 9.7 years in Group 2. Fourteen patients had high‐grade Ta tumours and five had T1 tumours. While 12 patients had responded to the BCG, seven patients did not respond to the BCG. There was no correlation between mast cell mediators and BCG response. The N‐methylhistamine and histamine levels significantly increased with the onset of immunotherapy, and N‐methylhistamine levels significantly decreased when immunotherapy was terminated (P < .05). The pre‐BCG estimated marginal mean values of N‐methylhistamine were significantly higher in Group 1 than in Group 2 (P < .05).
Conclusions
Our study is the first to identify the changes in mast cell mediators with the onset of immunotherapy and in presence of bladder cancer. However, these mediators cannot predict patients’ response to immunotherapy.</description><subject>Administration, Intravesical</subject><subject>Aged</subject><subject>BCG Vaccine - therapeutic use</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Histamine</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunity</subject><subject>Immunotherapy</subject><subject>Invasiveness</subject><subject>Mast Cells</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Prospective Studies</subject><subject>Tryptase</subject><subject>Tumors</subject><subject>Urinary Bladder Neoplasms - drug therapy</subject><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kbFu1TAUhi1ERUth4QGQJRaElGLHcRxPCC7QFlWCAWbrxDnp9VViBztp1Y21W5-xT1Jf7oWBAUuW_-HzJ_v8hLzg7ITn9dZt7HTChZb6ETniqioLXlb8cc6ibgrJBD8kT1PaMFZK2bAn5FAIUWsm9RG5_RjoEp2HeENHSDO1OAx0xM7BHGKiU8zRztSN4-KRRkxT8AnpHOiH1Sl1nk4wO_RzotduXmfejVvX2l2u73_dXUbokPrgcx6XZAfMV64guSuk7QBdh5Fa8Bbju2fkoIch4fP9eUx-fP70fXVWXHw9PV-9vyis0EIXtu9EXeuaVY2oqroH1ZbIbMOgVhYbUAg9b1SXNwITLbCytbzpNUiFVYfimLzeeacYfi6YZjO6tP01eAxLMmWlRMVULWRGX_2DbsISfX6dKSWXWkkty0y92VE2hpQi9mY_BMOZ2RZktgWZ3wVl-OVeubR5yn_RP41kgO-AazfgzX9U5vzL6ttO-gAqdp7z</recordid><startdate>202105</startdate><enddate>202105</enddate><creator>Simsekoglu, Muhammed Fatih</creator><creator>Kaleler, Islim</creator><creator>Onal, Bulent</creator><creator>Demirdag, Cetin</creator><creator>Citgez, Sinharib</creator><creator>Uslu, Ezel</creator><creator>Erozenci, Ahmet</creator><creator>Talat, Zubeyr</creator><general>Hindawi Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8912-9155</orcidid><orcidid>https://orcid.org/0000-0002-2712-7955</orcidid><orcidid>https://orcid.org/0000-0003-0540-2693</orcidid><orcidid>https://orcid.org/0000-0003-0645-4129</orcidid><orcidid>https://orcid.org/0000-0003-3925-0851</orcidid><orcidid>https://orcid.org/0000-0001-7577-7955</orcidid><orcidid>https://orcid.org/0000-0002-3897-2951</orcidid><orcidid>https://orcid.org/0000-0002-6389-5353</orcidid></search><sort><creationdate>202105</creationdate><title>Do urinary mast cell mediators predict immune response to BCG in patients with primary high‐grade non‐muscle invasive bladder cancer?</title><author>Simsekoglu, Muhammed Fatih ; Kaleler, Islim ; Onal, Bulent ; Demirdag, Cetin ; Citgez, Sinharib ; Uslu, Ezel ; Erozenci, Ahmet ; Talat, Zubeyr</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3939-cfd366960483446fa7b2e0c80a67ce8a7eaf187d187ea03ba02bc18f9a57e4de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Administration, Intravesical</topic><topic>Aged</topic><topic>BCG Vaccine - therapeutic use</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Histamine</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunity</topic><topic>Immunotherapy</topic><topic>Invasiveness</topic><topic>Mast Cells</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Prospective Studies</topic><topic>Tryptase</topic><topic>Tumors</topic><topic>Urinary Bladder Neoplasms - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Simsekoglu, Muhammed Fatih</creatorcontrib><creatorcontrib>Kaleler, Islim</creatorcontrib><creatorcontrib>Onal, Bulent</creatorcontrib><creatorcontrib>Demirdag, Cetin</creatorcontrib><creatorcontrib>Citgez, Sinharib</creatorcontrib><creatorcontrib>Uslu, Ezel</creatorcontrib><creatorcontrib>Erozenci, Ahmet</creatorcontrib><creatorcontrib>Talat, Zubeyr</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Simsekoglu, Muhammed Fatih</au><au>Kaleler, Islim</au><au>Onal, Bulent</au><au>Demirdag, Cetin</au><au>Citgez, Sinharib</au><au>Uslu, Ezel</au><au>Erozenci, Ahmet</au><au>Talat, Zubeyr</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Do urinary mast cell mediators predict immune response to BCG in patients with primary high‐grade non‐muscle invasive bladder cancer?</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><addtitle>Int J Clin Pract</addtitle><date>2021-05</date><risdate>2021</risdate><volume>75</volume><issue>5</issue><spage>e13959</spage><epage>n/a</epage><pages>e13959-n/a</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract>Background
Mast cells play a critical role in cancer‐associated immunity. We aimed to determine the predictive value of urinary mast cell mediators in patients with non‐muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette‐Guérin (BCG) immunotherapy.
Methods
In this prospective study, 19 patients who received immunotherapy because of NMIBC (Group 1) and 19 healthy participants (Group 2) were enrolled. Urine samples were collected to assay N‐methylhistamine, histamine, and tryptase levels immediately before the first BCG instillation, immediately after the third and sixth instillations, and 4 weeks after the sixth instillation in Group 1 and at a single visit in Group 2. The changes in urinary markers because of BCC response, BCG instillation, and the presence of NMIBC were assessed.
Results
The average age was 56.1 ± 10.5 years in Group 1 and 52.6 ± 9.7 years in Group 2. Fourteen patients had high‐grade Ta tumours and five had T1 tumours. While 12 patients had responded to the BCG, seven patients did not respond to the BCG. There was no correlation between mast cell mediators and BCG response. The N‐methylhistamine and histamine levels significantly increased with the onset of immunotherapy, and N‐methylhistamine levels significantly decreased when immunotherapy was terminated (P < .05). The pre‐BCG estimated marginal mean values of N‐methylhistamine were significantly higher in Group 1 than in Group 2 (P < .05).
Conclusions
Our study is the first to identify the changes in mast cell mediators with the onset of immunotherapy and in presence of bladder cancer. However, these mediators cannot predict patients’ response to immunotherapy.</abstract><cop>England</cop><pub>Hindawi Limited</pub><pmid>33369059</pmid><doi>10.1111/ijcp.13959</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-8912-9155</orcidid><orcidid>https://orcid.org/0000-0002-2712-7955</orcidid><orcidid>https://orcid.org/0000-0003-0540-2693</orcidid><orcidid>https://orcid.org/0000-0003-0645-4129</orcidid><orcidid>https://orcid.org/0000-0003-3925-0851</orcidid><orcidid>https://orcid.org/0000-0001-7577-7955</orcidid><orcidid>https://orcid.org/0000-0002-3897-2951</orcidid><orcidid>https://orcid.org/0000-0002-6389-5353</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-5031 |
| ispartof | International journal of clinical practice (Esher), 2021-05, Vol.75 (5), p.e13959-n/a |
| issn | 1368-5031 1742-1241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2473407635 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Administration, Intravesical Aged BCG Vaccine - therapeutic use Bladder cancer Cancer Histamine Humans Immune response Immunity Immunotherapy Invasiveness Mast Cells Middle Aged Neoplasm Recurrence, Local Prospective Studies Tryptase Tumors Urinary Bladder Neoplasms - drug therapy |
| title | Do urinary mast cell mediators predict immune response to BCG in patients with primary high‐grade non‐muscle invasive bladder cancer? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T05%3A35%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Do%20urinary%20mast%20cell%20mediators%20predict%20immune%20response%20to%20BCG%20in%20patients%20with%20primary%20high%E2%80%90grade%20non%E2%80%90muscle%20invasive%20bladder%20cancer?&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=Simsekoglu,%20Muhammed%20Fatih&rft.date=2021-05&rft.volume=75&rft.issue=5&rft.spage=e13959&rft.epage=n/a&rft.pages=e13959-n/a&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1111/ijcp.13959&rft_dat=%3Cproquest_cross%3E2515975952%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2515975952&rft_id=info:pmid/33369059&rfr_iscdi=true |